Siga Technologies Inc Quick Ratio (SIGAQ) starting from the fourth quarter 2019 to fourth quarter 2018, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Siga Technologies Inc  (SIGAQ)

Siga Technologies Inc's Quick Ratio

SIGAQ's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2019, Quick Ratio fell to 0.71 below Siga Technologies Inc average.

Within Major Pharmaceutical Preparations industry 404 other companies have achieved higher Quick Ratio than Siga Technologies Inc in fourth quarter 2019. While Quick Ratio total ranking in the fourth quarter 2019 has deteriorated compared to the prior quarter from 907 to 2150.

Explain Quick Ratio?
How much Cash & cash equivalents SIGAQ´s has?
What are SIGAQ´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SIGAQ Quick Ratio (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Sep 30 2018)
Q3		 (Jun 30 2018)
Q2
Y / Y Current Liabilities Change -75.94 % 193.55 % - - -
Y / Y Cash & cash equivalent Change 201.94 % 259.69 % - - -
Quick Ratio MRQ 0.71 7.56 10.03 20.76 0.06
SIGAQ's Total Ranking # 2150 # 907 # 135 # #
Seq. Current Liabilities Change 677.69 % 6.05 % 113.67 % -98.63 % 9387.95 %
Seq. Cash & cash equivalent Change -26.81 % -20.06 % 3.18 % 400.14 % -12.81 %



Quick Ratio fourth quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 405
Healthcare Sector # 692
Overall Market # 2150


Quick Ratio Statistics
High Average Low
20.76 7.55 0.06
(Sep 30 2018)   (Jun 30 2018)




Financial Statements
Siga Technologies Inc's Current Liabilities $ 92 Millions Visit SIGAQ's Balance sheet
Siga Technologies Inc's Cash & cash equivalent $ 65 Millions Visit SIGAQ's Balance sheet
Source of SIGAQ's Sales Visit SIGAQ's Sales by Geography


Cumulative Siga Technologies Inc's Quick Ratio

SIGAQ's Quick Ratio for the trailling 12 Months

SIGAQ Quick Ratio

 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Sep 30 2018)
12 Months		 (Jun 30 2018)
12 Months
Y / Y Current Liabilities TTM Growth -68.89 % 10087.85 % - - -
Y / Y Cash & cash equivalent TTM Growth 706.1 % 1232.87 % - - -
Quick Ratio TTM 3.12 0.81 0.66 0.4 0.12
Total Ranking TTM # 4506 # 4815 # 4825 # #
Seq. Current Liabilities TTM Growth -70.72 % 1.94 % 2.85 % 1.35 % 9487.95 %
Seq. Cash & cash equivalent TTM Growth 13.21 % 24.2 % 72.19 % 232.96 % 87.19 %

Quick ratio ranking by company, industry and sector >> Back to SIGAQ Financial Strength Comparisons >> Go to Compare SIGAQ Quick Ratio to its Competitors

On the trailing twelve months basis SIGAQ Cash & cash equivalent more than doubled by 201.94 % in Q4 2019 year on year, while Current Liabilities more than doubled to $92 millions, this led to increase in in Siga Technologies Inc's Quick Ratio to 3.12, above SIGAQ average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 454 other companies have achieved higher Quick Ratio than Siga Technologies Inc. While Quick Ratio overall ranking has improved so far to 4506, from total ranking during the twelve months ending third quarter 2019 at 4815.

Explain Quick Ratio?
How much Cash & cash equivalents SIGAQ´s has?
What are SIGAQ´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 455
Healthcare Sector # 871
Within the Market # 4506


trailing twelve months Quick Ratio Statistics
High Average Low
3.12 1.21 0.25
(Dec 31 2019)   (Sep 30 2018)




Companies with similar Quick Ratio in the quarter ending Dec 31 2019, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2019 MRQ Cash & cash equivalentDec 31 2019 MRQ Current Liabilities
Stealth Biotherapeutics Corp  1.93 $ 50.768  Millions$ 26.328  Millions
Evofem Biosciences Inc   1.91 $ 23.804  Millions$ 12.462  Millions
Skye Bioscience Inc   1.89 $ 1.835  Millions$ 0.971  Millions
Imunon Inc   1.88 $ 14.861  Millions$ 7.895  Millions
Inhibitor Therapeutics Inc   1.86 $ 0.804  Millions$ 0.431  Millions
Myovant Sciences Ltd   1.86 $ 98.888  Millions$ 53.296  Millions
Pharming Group N v   1.83 $ 74.348  Millions$ 40.646  Millions
Compass Pathways Plc  1.80 $ 24.984  Millions$ 13.869  Millions
Tuhura Biosciences Inc   1.80 $ 3.719  Millions$ 2.070  Millions
Quantum Biopharma Ltd   1.78 $ 5.968  Millions$ 3.361  Millions
Scorpius Holdings inc   1.75 $ 14.754  Millions$ 8.435  Millions
Aclaris Therapeutics Inc   1.74 $ 39.078  Millions$ 22.432  Millions
Actinium Pharmaceuticals Inc  1.74 $ 9.304  Millions$ 5.344  Millions
Hutchmed china Limited  1.73 $ 218.066  Millions$ 126.359  Millions
Citius Pharmaceuticals Inc   1.73 $ 7.951  Millions$ 4.608  Millions
Cti Biopharma Corp   1.70 $ 33.666  Millions$ 19.756  Millions
Keros Therapeutics Inc   1.69 $ 7.020  Millions$ 4.153  Millions
Alx Oncology Holdings Inc  1.68 $ 9.017  Millions$ 5.364  Millions
Tg Therapeutics Inc   1.66 $ 140.435  Millions$ 84.449  Millions
Organogenesis Holdings Inc   1.65 $ 60.174  Millions$ 36.444  Millions
Biora Therapeutics Inc   1.57 $ 33.042  Millions$ 21.076  Millions
Durect Corp  1.53 $ 64.674  Millions$ 42.340  Millions
Clene Inc   1.53 $ 8.788  Millions$ 5.756  Millions
Cns Pharmaceuticals Inc   1.51 $ 0.283  Millions$ 0.187  Millions
Prophase Labs Inc   1.46 $ 1.360  Millions$ 0.933  Millions
Sellas Life Sciences Group Inc   1.45 $ 7.377  Millions$ 5.073  Millions
Dicerna Pharmaceuticals Inc   1.44 $ 348.881  Millions$ 241.735  Millions
Decoy Therapeutics Inc   1.43 $ 3.739  Millions$ 2.611  Millions
Damora Therapeutics Inc   1.42 $ 11.294  Millions$ 7.927  Millions
Rigel Pharmaceuticals Inc  1.42 $ 98.078  Millions$ 69.139  Millions

Date modified: 2026-09-08T15:22:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.